Related Experiment Video
Updated: Jul 4, 2025

Isolation of Macrophage Subsets and Stromal Cells from Human and Mouse Myocardial Specimens
Published on: December 17, 2019
Mineralocorticoid receptor promotes cardiac macrophage inflammaging
Daniela Fraccarollo1, Robert Geffers2, Paolo Galuppo3
1Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str.1 30625, Hannover, Germany. fraccarollo.daniela@mh-hannover.de.
Abstract:
Inflammaging, a pro-inflammatory status that characterizes aging and primarily involving macrophages, is a master driver of age-related diseases. Mineralocorticoid receptor (MR) activation in macrophages critically regulates inflammatory and fibrotic processes. However, macrophage-specific mechanisms and the role of the macrophage MR for the regulation of inflammation and fibrotic remodeling in the aging heart have not yet been elucidated. Transcriptome profiling of cardiac macrophages from male/female young (4 months-old), middle (12 months-old) and old (18 and 24 months-old) mice revealed that myeloid cell-restricted MR deficiency prevents macrophage differentiation toward a pro-inflammatory phenotype. Pathway enrichment analysis showed that several biological processes related to inflammation and cell metabolism were modulated by the MR in aged macrophages. Further, transcriptome analysis of aged cardiac fibroblasts revealed that macrophage MR deficiency reduced the activation of pathways related to inflammation and upregulation of ZBTB16, a transcription factor involved in fibrosis. Phenotypic characterization of macrophages showed a progressive replacement of the TIMD4+MHC-IIneg/low macrophage population by TIMD4+MHC-IIint/high and TIMD4-MHC-IIint/high macrophages in the aging heart. By integrating cell sorting and transwell experiments with TIMD4+/TIMD4-macrophages and fibroblasts from old MRflox/MRLysMCre hearts, we showed that the inflammatory crosstalk between TIMD4- macrophages and fibroblasts may imply the macrophage MR and the release of mitochondrial superoxide anions. Macrophage MR deficiency reduced the expansion of the TIMD4- macrophage population and the emergence of fibrotic niches in the aging heart, thereby protecting against cardiac inflammation, fibrosis, and dysfunction. This study highlights the MR as an important mediator of cardiac macrophage inflammaging and age-related fibrotic remodeling.
Insights
Targeting the mineralocorticoid receptor (MR) in cardiac macrophages can combat aging-related inflammation and fibrosis. This study reveals MR
Area of Science:
- Cardiovascular Biology
- Immunology
- Aging Research
Background:
- Aging is characterized by inflammaging, a pro-inflammatory state driven by macrophages, contributing to age-related diseases.
- The mineralocorticoid receptor (MR) in macrophages regulates inflammation and fibrosis, but its role in the aging heart is unclear.
Purpose of the Study:
- To investigate the role of macrophage-specific MR in regulating cardiac inflammation and fibrosis during aging.
- To elucidate the mechanisms by which macrophage MR influences cardiac aging and dysfunction.
Main Methods:
- Transcriptome profiling of cardiac macrophages and fibroblasts from young and aged mice.
- Analysis of macrophage phenotypes and their interaction with fibroblasts.
- Utilizing myeloid cell-restricted MR-deficient mouse models.
Main Results:
- Myeloid cell-specific MR deficiency prevented pro-inflammatory macrophage differentiation and modulated inflammation/metabolism pathways in aged macrophages.
- Macrophage MR deficiency reduced inflammation and fibrosis-related pathways in cardiac fibroblasts.
- MR deficiency in macrophages decreased the TIMD4-negative macrophage population and protected against cardiac inflammation, fibrosis, and dysfunction.
Conclusions:
- The macrophage MR is a key mediator of cardiac inflammaging and age-related fibrotic remodeling.
- Targeting macrophage MR offers a potential therapeutic strategy to mitigate age-related cardiac dysfunction.
More Related Videos
Related Concept Videos
Inflammation
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

